Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Thermo Fisher Scientific, Insight Genetics, Allele Biotech

Thermo Fisher Scientific Invitrogen Collibri Stranded RNA Library Prep Kits for Illumina Systems

Thermo Fisher Scientific has launched a new line of Invitrogen next-generation sequencing library preparation kits that are compatible with Illumina sequencing systems. The Invitrogen Collibri Stranded RNA Library Prep Kits for Illumina Systems come in two versions; one for whole transcriptome sequencing that includes ribosomal depletion, and one for mRNA sequencing that lacks ribosomal depletion. The firm said that kits are currently available outside of the Americas.


Insight Genetics TNBCtype

Insight Genetics has launched Insight TNBCtype, a new test for categorizing triple negative breast cancers (TNBC) into distinct molecular subtypes. Offered through the firm's CLIA-certified and CAP-accredited lab, Insight Molecular Labs, the new test is intended to help advance prospective clinical trials of targeted therapies for TNBC patients.


Allele Biotech Stem Cells

Allele Biotech has produced its initial batch of six induced pluripotent stem cell (iPSC) lines. The firm's iPSCs were created using its mRNA technologies, with full cGMP monitoring and documentation starting from donor consent, screening, and tissue biopsy. In addition to iPSC generation and differentiation, customers can use Allele's mRNA platform to engineer human iPSCs in a one-time genetic modification event to create a clonal iPSC line that can be developed into a master cell bank.


For more new products and services, please visit the New Products page on our website.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.